

Polygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes

Matthew Moll^{1,2,3,24}, Julian Hecker^{1,24}, John Platig⁴, Jingzhou Zhang⁵, Auyon J. Ghosh⁶, Katherine A. Pratte⁷, Rui-Sheng Wang¹, Davin Hill⁸, Iain R. Konigsberg⁹, Joe W. Chiles III¹⁰, Craig P. Hersh^{1,2,24}, Peter J. Castaldi^{1,10,24}, Kimberly Glass^{1,24}, Jennifer G. Dy⁸, Don D. Sin¹², Ruth Tal-Singer¹³, Majd Mouded¹⁴, Stephen I. Rennard¹⁵, Gary P. Anderson¹⁶, Gregory L. Kinney¹⁷, Russell P. Bowler¹⁸, Jeffrey L. Curtis^{19,20}, Merry-Lynn McDonald^{9,21,22}, Edwin K. Silverman^{1,2,24}, Brian D. Hobbs^{23†}, Michael H. Cho^{1,2,24†}

Affiliations:

1 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115.

2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115.

3 Division of Pulmonary, Critical Care, Sleep and Allergy. Veterans Affairs Boston Healthcare System, West Roxbury, MA, 02123

4 Center for Public Health Genomics, University of Virginia, Charlottesville, VA, 22903

5 The Pulmonary Center, Boston University Medical Center, Boston, MA 02118

6 Division of Pulmonary, Critical Care, and Sleep Medicine, SUNY Upstate Medical University, Syracuse, NY, 13210.

7 Department of Biostatistics, National Jewish Health, Denver, CO, 80206.

8 Department of Electrical and Computer Engineering, Northeastern University, Boston, MA, 02115.

9 Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.

10 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233.

11 Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115.

12 Centre for Heart Lung Innovation, St. Paul's Hospital, and Department of Medicine (Respiratory Division), University of British Columbia, Vancouver, BC, Canada.

13 Global Allergy and Airways Patient Platform, Vienna, AU.

14 Novartis Institute for Biomedical Research, Cambridge, MA.

15 Division of Pulmonary, Critical Care, and Sleep Medicine, University of Nebraska, Omaha, NE 68198

16 Lung Health Research Centre, Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Victoria, Australia.

17 Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045

18 Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, 80206.

19 Division of Pulmonary and Critical Care Medicine, University of Michigan School of Medicine, Ann Arbor, MI, 48109.

20 Medical Service, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, 48109

21 Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 701, 19th Street S., LHRB 440, Birmingham, AL, 35233.

22 Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, 35233.

23 Regeneron Pharmaceutical, Tarrytown, NY

24 Harvard Medical School, Boston, MA, 02115.

† = Jointly supervised and co-senior authors

Correspondence:

Michael H. Cho, MD, MPH
181 Longwood Avenue
Boston, MA 02115
remhc@channing.harvard.edu

This article has an online data supplement.

Funding:

MM is supported by K08HL159318.

BDH is supported by NIH K08HL136928, U01 HL089856, and an Alpha-1 Foundation Research Grant.

JH is supported by P01 HL132825.

JHP is supported by NIH K25HL140186.

CPH is supported by NIH R01HL157879 and P01HL114501.

MHC is supported by NIH R01HL137927, R01HL135142, HL147148, and HL089856.

PJC is supported by NIH R01HL124233 and R01HL147326.

RPB is supported by NIH R01 HL137995 and R01 HL152735

EKS is supported by NIH R01 HL147148, U01 HL089856, R01 HL133135, R01 HL152728, and P01 HL114501.

Proteomic data generated for this proposal was supported by R01 HL137995.

The COPDGene project was supported by NHLBI grants U01 HL089897 and U01 HL089856 and by NIH contract 75N92023D00011. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. The ECLIPSE study (NCT00292552; GSK code SCO104960) was funded by GlaxoSmithKline.

Disclosures:

EKS received grant support from Bayer and Northpond Labs. BDH received grant support from Bayer. MHC has received grant support from Bayer. MM received grant support from Bayer and consulting fees from Sitka, TheaHealth, 2ndMD, and TriNetX. CPH reports grant support from Boehringer-Ingelheim, Novartis, Bayer and Vertex, outside of this study. PJC has received grant support from GlaxoSmithKline and Bayer and consulting fees from GlaxoSmithKline and Novartis. RTS received consulting fees from GSK, AstraZeneca, Roche, Itai and Beyond, Samay Health, Immunomet, ENA Respiratory, Teva, COPD Foundation and Vocalis Health. She is a retiree and shareholder of GSK and holds share options at ENA Respiratory. JLC received consulting fees from AstraZeneca PLC, CSL Behring, LLC, and Novartis Corporation. SIR received consulting fees from Verona Pharma, Sanofi, BeyondAir and the Alpha 1 Foundation. He is a founder and president of Great Plains Biometrix. He was an employee of AstraZeneca from 2015-2019 during which he received shares as part of his compensation that he owns.

Author contributions:

Study Design: Matthew Moll, Julian Hecker, Michael H. Cho, Brian D. Hobbs.

Acquisition, analysis, or interpretation of the data: Matthew Moll, Julian Hecker, Edwin K. Silverman, Auyon Ghosh, Don D. Sin, Peter J. Castaldi, Katherine Pratte, Russell Bowler, Brian D. Hobbs, Michael H. Cho.

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Matthew Moll, Julian Hecker, John Platig, Kimberly Glass, Brian D. Hobbs, Michael H. Cho.

Obtained funding: Edwin K. Silverman, Michael H. Cho, Matthew Moll

Word counts:

Abstract: 249

Manuscript: 3404

1 **ABSTRACT**

2 **Rationale:** Genetic variants and gene expression predict risk of chronic obstructive pulmonary
3 disease (COPD), but their effect on COPD heterogeneity is unclear.

4 **Objectives:** Define high-risk COPD subtypes using both genetics (polygenic risk score, PRS)
5 and blood gene expression (transcriptional risk score, TRS) and assess differences in clinical and
6 molecular characteristics.

7 **Methods:** We defined high-risk groups based on PRS and TRS quantiles by maximizing
8 differences in protein biomarkers in a COPDGene training set and identified these groups in
9 COPDGene and ECLIPSE test sets. We tested multivariable associations of subgroups with
10 clinical outcomes and compared protein-protein interaction networks and drug repurposing
11 analyses between high-risk groups.

12 **Measurements and Main Results:** We examined two high-risk omics-defined groups in non-
13 overlapping test sets (n=1,133 NHW COPDGene, n=299 African American (AA) COPDGene,
14 n=468 ECLIPSE). We defined “High activity” (low PRS/high TRS) and “severe risk” (high
15 PRS/high TRS) subgroups. Participants in both subgroups had lower body-mass index (BMI),
16 lower lung function, and alterations in metabolic, growth, and immune signaling processes
17 compared to a low-risk (low PRS, low TRS) reference subgroup. “High activity” but not “severe
18 risk” participants had greater prospective FEV₁ decline (COPDGene: -51 mL/year; ECLIPSE: -
19 40 mL/year) and their proteomic profiles were enriched in gene sets perturbed by treatment with
20 5-lipoxygenase inhibitors and angiotensin-converting enzyme (ACE) inhibitors.

21 **Conclusions:** Concomitant use of polygenic and transcriptional risk scores identified clinical and
22 molecular heterogeneity amongst high-risk individuals. Proteomic and drug repurposing analysis

23 identified subtype-specific enrichment for therapies and suggest prior drug repurposing failures

24 may be explained by patient selection.

25

26

27 **INTRODUCTION**

28 Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and
29 mortality worldwide¹. Although COPD is characterized by irreversible airflow obstruction, there
30 is marked heterogeneity amongst individuals in emphysema and airway pathology, exacerbation
31 incidence, and lung function decline^{2,3}. Identifying individuals at high risk for rapid COPD
32 progression or eventual severe disease is critically important to implement personalized
33 therapeutic approaches.

34 Large-scale omics data offer the potential to identify via a simple blood test high risk
35 groups that share distinct, targetable pathobiology. Genetics, quantified with polygenic risk
36 scores (PRSs), can identify individuals at high risk for coronary artery disease and guide
37 consideration of statin therapy earlier than advised by current guidelines⁴. In cancer, integrating
38 genetic and transcriptomic profiling can improve therapy recommendations and outcomes⁵. We
39 demonstrated that both a PRS and a transcriptional risk score (TRS) independently predict
40 COPD^{6,7}. Although the PRS and TRS were both based on spirometry measures, the scores are
41 not correlated⁷ and likely capture different aspects of lung pathobiology. Specifically, COPD
42 genetic risk loci are enriched for aspects of lung development and have a greater effect in early
43 COPD^{6,8}; in contrast, the COPD TRS is associated with markers of inflammation and lung
44 function decline and may reflect disease activity and propensity toward disease progression⁷.
45 Thus, it may be possible to leverage the different features of the PRS and TRS to identify
46 clinically and biologically distinct COPD subtypes.

47 Despite advances in omics-based risk prediction, important clinical translation questions
48 remain. Omics risk scores are usually standardized for statistical analyses, leaving the question
49 of how to use them to risk-stratify individuals⁹. Risk scores are also continuous measures, often

50 normally distributed; the issue of attempting to identify subtypes along a continuum has been
51 previously recognized¹⁰. Despite this limitation, there is a need to classify individuals to link
52 omics-defined high-risk groups, which might benefit from specific therapies, with specific
53 pathobiological processes and treatment decisions. COPD drug and drug repurposing candidates
54 have high failure rates in clinical trials¹¹, but it remains unknown if these therapies have failed
55 because of patient selection, which currently does not utilize omics or other biomarkers.

56 The PRS was effective for predicting COPD severity and incident COPD, while the TRS
57 was better at predicting FEV₁ decline; combining both risk scores may identify subgroups at risk
58 for multiple important COPD outcomes. Therefore, we hypothesized that our published PRS and
59 TRS, both based on spirometry, could identify COPD subtypes (i.e., heterogeneity) within high-
60 risk groups with clinical and biological differences in two cohorts of ever-smokers. We aimed to
61 develop a novel approach for how omics risk scores can be applied to populations and leveraged
62 for precision medicine. We used proteomics to obtain an additional biological view of omics-
63 defined subgroups and performed in silico drug repurposing analyses to identify potential
64 subgroup-specific drug repurposing candidates.

65 **METHODS**

66 **Study populations**

67 All study participants provided written informed consent and studies were approved by
68 local Institutional Review Boards. Details regarding genotyping, RNA-sequencing, gene
69 expression microarray, and proteomics data acquisition and processing are available in the
70 Supplement.

71 *COPDGene*

72 We included Genetic Epidemiology of COPD (COPDGene) study (ClinicalTrials.gov
73 Identifier: NCT00608764) participants with single nucleotide polymorphism (SNP) genotyping,
74 RNA-sequencing, and SomaScan proteomic data to calculate the PRS, TRS, and performed
75 differential protein expression analyses, respectively.

76

77 *ECLIPSE*

78 As previously described⁷, we included Evaluation of COPD Longitudinally to Identify
79 Predictive Surrogate End-points (ECLIPSE) study (ClinicalTrials.gov Identifier: NCT00292552)
80 participants with SNP genotyping data, whole blood microarray data, and at least two FEV₁
81 measurements.

82

83 Additional details for both cohorts are in the supplement.

84

85 **Polygenic and transcriptional risk scores**

86 The COPD PRS and TRS were both based on spirometry and previously described^{6,7}; more
87 details can be found in the supplement.

88

89 **Proteomic data**

90 Blood proteomic data were measured using SomaScan v4.0, which uses aptamers (i.e.
91 SOMAmers) to quantify 4,776 unique human proteins. Further details regarding SomaScan data
92 and preparation can be found in the Supplement and here¹².

93 **Statistical analysis**

94 *Overview of study design*

95 To identify high-risk subgroups based on continuous scores, we used the same previously
96 defined COPDGene training set⁷, and tested among PRS and TRS quantiles to maximize the
97 number of associated differentially expressed proteins across the resulting subtype partitions
98 (**Fig. 1**). We then determined the raw (non-standardized) score cut offs associated with the
99 corresponding percentile values in the COPDGene training set. This approach facilitated
100 classifying each participant in the COPDGene testing set and the external ECLIPSE validation
101 set into an omics-defined subtype. We characterized the newly-defined subtypes using proteomic
102 network and drug repurposing analyses, and applied multivariable linear regressions to test the
103 association of subtypes with COPD-related outcomes.

104

105 *Determining risk score divisions and identifying omics-defined subtypes*

106 Omics-based risk scores are typically standardized prior to statistical analysis, and
107 therefore, have a normal distribution and by design do not lend themselves to clustering analyses
108 (**Figure S1**). Yet, for clinical application, patients need to be categorized into groups. First, to
109 determine whether one or more clusters are optimal, we calculated the gap statistic based on the
110 PRS and TRS using the `clusGap` function (cluster R package) with a maximum of 8 kmeans
111 clusters and 500 bootstrap iterations. The gap statistic provides a measure of dispersion for each

112 cluster and compares this dispersion metric to the expected dispersion under the null
113 distribution¹³; thus, the difference (or “gap”) between the observed and expected within cluster
114 dispersion is used to calculate the gap statistic and the maximum gap statistic over a range of
115 cluster numbers indicates the optimal number of clusters.

116 As an alternative to clustering, individuals are commonly placed into omics risk-score
117 quantiles, and participants in each quantile are compared to those in the lowest risk quantile^{4,6,14}.
118 To extend this approach to two separate omics risk scores is more complex, as fewer
119 subdivisions lead to larger group sizes and more statistical power, but more subdivisions allow a
120 more extreme comparison group. As genetic and transcriptomic data were used to define the
121 subtypes, proteomics would provide a third “view” of the data. Thus, to determine the optimal
122 quantiles we split the PRS and TRS into 2 to 3 quantiles (minimum of 4 and maximum of 9
123 groups) and tested to see what group divisions maximized the number of associated differentially
124 expressed proteins using limma¹⁵, comparing each quantile category to the lowest quantile. To
125 test the sensitivity of the groups to partitioning, we also examined clinical characteristics for
126 each combination of these partitions. Benjamini-Hochberg¹⁶ false discovery rate (FDR)-adjusted
127 p-values less than 0.05 were considered significant. The number of significantly differentially
128 expressed proteins associated with each omics risk score category was summed.

129

130 *Clinical comparisons of omics-defined subtypes*

131 We compared clinical characteristics across omics-defined subtypes using the tableone R
132 package. In COPDGene, transcriptomic and proteomic data were collected at the 5-year follow
133 up visit (i.e., “Phase 2”), so we examined differences in anthropometry (including change in BMI

134 per year ($\text{Kg/m}^2/\text{year}$) from enrollment to the 5-year follow up visit), spirometry (including
135 prospective FEV_1 change (from 5- to 10-year follow up visits)), and CT measures of emphysema
136 (quantitative emphysema on inspiratory CT scans (% LAA < -950 HU)¹⁷, 15th percentile of lung
137 density histogram on inspiratory CT scans (Perc15)¹⁸) and of airway thickening (wall area
138 percent (WA%)¹⁷ and square root of wall area of a hypothetical internal perimeter of 10 mm
139 (Pi10)¹⁹) at the 5-year follow up visit. In ECLIPSE, we examined the same outcomes but
140 longitudinal follow up was from the time of study enrollment to the 3-year follow up visit.

141
142 Further details regarding outcomes and regression model specifications are in the Supplementary
143 Methods.

144
145 *Biological characterization of omics-defined subtypes*

146 We performed differential gene and protein expression analyses (accepting FDR-adjusted
147 p-values <0.05), comparing high risk subtypes to the reference group, defined as the group with
148 the lowest PRS and TRS quantiles. We mapped differentially expressed proteins to the human
149 protein-protein interactome²⁰ and performed Reactome²¹ pathway enrichment, STRING²⁴ and
150 Enrichr²²⁻²⁴ analyses; additional details are in the supplement.

151

152 **RESULTS**

153 *Characteristics of study populations*

154 We included 3,274 participants across two cohorts of individuals who smoked. The
155 COPDGene training and testing sets are similar in demographic and spirometry characteristics
156 (**Table 1**). Compared to COPDGene, ECLIPSE participants were more likely to be younger,
157 male, to have a greater number of smoking pack-years, a lower FEV₁ % predicted, and lower
158 FEV₁/FVC, and were less likely to be current smokers.

159 *Defining polygenic and transcriptional risk score divisions*

160 Participants plotted on the axes of PRS and TRS exist along a continuum (**Figure S1**), as
161 is the case for spirometric measures of COPD severity (i.e., FEV₁ and FEV₁/FVC^{10,25}). We
162 calculated the gap statistic over a range of kmeans cluster numbers in the COPDGene training
163 set, and consistent with visual inspection of **Figure S1**, we observed that one cluster yields the
164 highest gap statistic, indicating that there are no clusters (**Figure S2**). As an alternative approach
165 to clustering, we applied the common practice of dividing risk scores into quantiles, though the
166 optimal quantiles balancing sufficiently high risk yet adequate sample size are not clear. Thus,
167 we tested four combinations of partitioned omics risk scores, using protein expression
168 differences (not used in the PRS and TRS) between groups. We observed that dichotomizing
169 PRS and dividing TRS into tertiles yielded the greatest number of differentially expressed
170 proteins (**Table S1**). We then applied these same quantiles to the COPDGene testing set and
171 ECLIPSE participants (**Fig. 2**). To test the robustness of subgroups to specific partitions, we also
172 examined 4 to 9 subdivisions, and noted stable clinical characteristics of the highest (“low

173 PRS/high TRS” and “high PRS/high PRS”) and lowest risk (“low PRS/low TRS”) groups (**Table**
174 **S2**).

175 *Polygenic and transcriptional risk scores identify “high disease activity” and “severe*
176 *disease risk” subtypes*

177 We observed, as expected, heterogeneity amongst the two high-risk (i.e., high TRS)
178 groups (**Table 2**). We compared these high-risk subtypes to a reference group, which was
179 defined as the lowest omics risk group (i.e., “low PRS/low TRS” subtype). Compared to the
180 reference group, the two high-TRS risk groups (i.e., “low PRS/high TRS” and “high PRS/high
181 TRS”) demonstrated decreased BMI, lower spirometry measures, more emphysema, and thicker
182 airways across testing cohorts (**Table 2**). Both groups had similar mean adjusted prospective
183 FEV₁ decline in the COPDGene testing set compared to the reference group, but this finding was
184 only consistent for the “low PRS/high TRS” group in ECLIPSE (-40 mL/year).

185 We then performed linear regression analyses on selected COPD-related outcomes. We
186 compared anthropometric, spirometry, CT, and other COPD-related outcomes across COPDGene
187 and ECLIPSE (**Table 3**, **Table S3**). Compared to the reference group, high-risk groups
188 exhibited lower spirometry, more emphysema, and thicker airways (**Table 3**). While none of the
189 adjusted FEV₁ decline measures were statistically significant, the “low PRS, high TRS” means
190 were consistent between COPDGene and ECLIPSE (-30ml/yr and -24ml/year, P = 0.15 and P =
191 0.11, respectively), despite that COPDGene participants had only two FEV₁ measurements while
192 ECLIPSE participants had up to six FEV₁ measurements. Given the clinical relevance of
193 accelerated FEV₁ decline in the “low PRS/high TRS” group, we renamed this group the “high
194 disease activity” subtype. While the “high PRS/high TRS” group did not have replicable FEV₁
195 decline across cohorts, this group had the lowest lung function and most emphysema; therefore,

196 we renamed this group the “severe disease risk” subtype. In COPDGene NHW participants only,
197 the “high disease activity” subtype also exhibited a trend toward greater decline in BMI
198 compared to the reference group ($\beta = -0.154$ [95% CI: -0.333 to 0.0253], $p=0.094$).

199

200 *Biological characterization and drug repurposing analyses of subtypes*

201 Having identified clinical differences between the two high-risk groups, we sought to
202 characterize biological differences between these subtypes. We performed differential gene and
203 protein expression analyses between the “high disease activity” and “severe disease risk”
204 subtypes and the reference group in the COPDGene NHW testing set (**Tables S4-S6**). The “high
205 disease activity” subtype had 14 and the “severe disease risk” subtype had 2 differentially
206 expressed proteins (**Table S6**). We did not observe differentially expressed genes or proteins
207 when directly comparing high risk groups. We examined how the PRS affects differential gene
208 expression associated with COPD case-control status as detailed in the supplement
209 (Supplementary Results and **Table S7**)

210

211 We mapped differentially expressed proteins associated with each high-risk subtype in the
212 COPDGene testing set to the human protein-protein interactome²⁰ and used the mapped proteins
213 as seed proteins to construct STRING PPI networks (**Figures 3 and 4**) with associated MCL
214 clusters (**Table S8**) and perform pathway enrichment analyses (**Table S9**). To identify subtype-
215 specific drug repurposing candidates, we used these same seed proteins to perform enrichment
216 analyses on the MAGMA Drugs and Disease database²⁶. Both subtypes demonstrated
217 enrichment proteomic profiles suggesting potential treatment with ACE inhibitors, thyroid

218 medications, carvedilol, bromocriptine, and lovastatin; the “high disease activity” subtype also
219 had significant findings for 5-lipoxygenase inhibitors, fomepizole, and galantamine, while the
220 “severe disease risk” (**Table S10**) subtype had significant findings for atypical antipsychotics.

221

222 **DISCUSSION**

223 In this study of 3,274 ever-smokers from two cohorts, we used blood-based polygenic
224 (PRS) and transcriptional (TRS) risk scores to identify heterogeneity within high-risk
225 individuals, defining “high disease activity” and “severe disease risk” COPD subtypes.
226 Compared to a reference group, both subtypes had lower mean BMI values and alterations in
227 metabolic, growth, and immune signaling processes. “High disease activity” participants
228 exhibited prospective FEV₁ decline across both replication cohorts, albeit with a non-significant
229 (though directionally consistent) association in multivariable models adjusted for baseline FEV₁.
230 “Severe disease risk” participants had low spirometry measures with high quantitative
231 emphysema and thick airways. We identified biological processes and drug repurposing
232 candidates associated with each subtype, including therapies previously tested in COPD clinical
233 trials. Our study demonstrates how omics risk scores can identify COPD subtypes with
234 associated clinical and biological characteristics that can be leveraged for therapeutic
235 interventions.

236 Linking omics-defined high-risk groups to specific pathobiology is an active area of
237 research that we now extend to lung disease. In schizophrenia, PRS-defined high risk groups
238 were biologically characterized using weighted gene co-expression network analyses²⁷. Other
239 approaches have incorporated gene expression into PRSs to improve prediction and imply

240 biological mechanisms^{28–30}. Here, we used genetic and transcriptomic data to define subtypes,
241 and then leveraged proteomic differences between groups to understand subtype biology.
242 Importantly, our results suggest that different omics risk scores are not interchangeable, i.e., a
243 higher omics risk score will not always have the same association with specific outcomes.
244 Individuals with the highest transcriptomic quantile exhibited different clinical and biological
245 features depending on their underlying polygenic risk. We also demonstrate that individuals may
246 exist along a continuum of COPD risk – i.e., there are no clusters – yet omics-defined subgroups
247 may have important clinical and biological differences. While we did not observe clusters, we
248 observed that omics-defined subgroups were robust to varying PRS and TRS subdivisions, with
249 the two high-risk groups (“low PRS/high TRS” and “high PRS/high TRS”) demonstrating stable
250 clinical characteristics across risk score subdivisions. Thus, genetics and transcriptomics may
251 provide alternative yet complementary views of lung function biology.

252 Of direct clinical relevance, the association of lower spirometry, greater emphysema and
253 observed FEV₁ decline across two cohorts suggests that the “high disease activity” subtype is a
254 targetable trait, the risk of which, might be modified by approved medications (5-lipoxygenase
255 inhibitors, angiotensin-converting enzyme (ACE) inhibitors, fomepizole, galantamine).
256 Fomepizole has not previously been implicated as a COPD drug repurposing candidate to our
257 knowledge. Galantamine is known to cause bronchospasm, and enrichment for proteins targeted
258 by galantamine suggests this drug is most likely to cause harm in this subtype of patients.
259 Although a randomized trial of the 5-lipoxygenase inhibitor, Zileuton, did not reduce length of
260 stay or treatment failure in patients hospitalized for COPD exacerbations, it was likely
261 underpowered³¹, and did not examine longer term outcomes. ACE inhibitors and angiotensin
262 receptor blockers (ARB) have been identified as COPD drug repurposing candidates. A recent

263 clinical trial showed failure of losartan to decrease emphysema progression³². Our drug
264 repurposing analyses implicated utility of captopril – not all ACE inhibitors and ARBs - in the
265 “high disease activity” but not the “severe disease risk” subtype. Conversely, our analysis
266 suggests potential benefit of atypical antipsychotics in the “severe disease risk” subtype. The
267 coincidence of schizophrenia and COPD is largely attributed to smoking, though a phenome-
268 wide association and polygenic risk analysis suggests that schizophrenia and obstructive lung
269 disease may have shared genetic mechanisms³³. While we adjusted for self-reported cigarette
270 smoking status, these measures are imperfect, and thus we cannot address whether shared
271 mechanisms are due to smoking behavior. A broader implication of the drug repurposing
272 analyses that merits validation is that previous failure of drugs in clinical trials was due to
273 heterogeneity in patient selection that could be overcome by omics-based subtyping.

274 The cachectic COPD patient, who may be prone to more exacerbations, is a well-
275 described clinical phenotype^{34–37}, and we observed that the “high disease activity” and “severe
276 disease risk” subtypes have lower mean BMI than other subtypes. Although pulmonary cachexia
277 has been proposed to occur only in severe COPD³⁸, we demonstrate additional heterogeneity
278 within lower BMI ever-smokers and identify a “high disease activity” subtype with less
279 spirometric severity and distinct biology. The “high disease activity” group may also overlap
280 with a previously identified comorbidity cachexia subgroup³⁹, and in the current analysis, we
281 identified molecular profiles that might guide therapy. Relevant to body composition, the
282 adipocyte product leptin exhibited altered expression in both subtypes, which has several
283 potential, not mutually exclusive interpretations. Leptin acts both as a hormone negatively
284 regulating hunger and adipocyte fat storage⁴⁰ and as a proinflammatory cytokine essential for
285 host defense^{41,42}.

286 The role of leptin in regulating hunger suggests it could be relevant to the “severe disease
287 risk” subtype, which had the largest effect size in leptin expression (-0.71 log-fold change); the
288 observed decrease in leptin could be a compensatory response to or share a causal relationship
289 with pulmonary cachexia. In addition, the lower leptin levels observed in malnourished
290 populations are associated with dysfunctional cell-mediated immunity and increased
291 susceptibility to infections^{41,43}. In COPD, elevated leptin concentrations have been reported in
292 the plasma and airways in some⁴⁴⁻⁴⁸, but not all studies⁴⁹, and has been identified as a potential
293 biomarker of emphysema progression^{50,51}. Our results suggest that “high disease activity” or
294 “severe disease risk” subtype individuals might exhibit humoral and cytokine profiles similar to
295 those seen in malnourished individuals with increased susceptibility to infections. It remains
296 unclear whether the observed peripheral blood proteomic alterations are merely a consequence of
297 disease activity, or a causal component of a positive feedback loop involved in driving disease
298 progression. The biomarkers used in this study are blood-based, making it difficult to identify the
299 relevant mechanisms in lung tissue. However, blood-based biomarkers are practical in a clinical
300 setting and follow up studies linking changes in these biomarkers to pathophysiologic
301 mechanism in lung tissue can help to bridge the gap between prediction and precision
302 therapeutics.

303 This study leveraged multiple omics data in the form of validated, replicated, risk scores,
304 to identify COPD subtypes in two cohorts of ever-smokers. One major challenge of this analysis
305 was determining how to subset subjects from a standardized, continuous distribution. To
306 overcome this limitation, we varied the number of quantiles and assessed which combination of
307 divisions yielded the greatest number of differentially expressed proteins, then identified
308 corresponding raw score cut-off values that allowed each participant in the COPDGene and

309 ECLIPSE testing sets to be categorized into an omics-defined subtype. We acknowledge that
310 there are other reasonable approaches for applying omics risk scores to identify COPD subtypes.

311 Individuals near the cut-off value for PRS might exist on a continuum between “high
312 disease activity” and “severe disease risk” subtypes, and these participants might be able to
313 transition between subtypes; regardless, defining thresholds and categories are an important step
314 toward clinical translation. We observed similar results in COPDGene AA participants,
315 including the “high disease activity” subtype association with FEV₁ decline in multivariable
316 analyses; however, additional work to optimize multi-ancestry genetic and omics-based
317 prediction is crucial to prevent omics technologies from becoming a vehicle for worsening
318 existing healthcare disparities⁵². We based our drug repurposing candidates on enrichment
319 analyses of proteomic profiles, but directionality of biological processes was not accounted for in
320 enrichment analyses; additional mechanistic and clinical trial validations are needed. Finally, we
321 identified two high-risk subtypes using this approach, but these do not explain all of COPD
322 heterogeneity, and there are almost certainly other important subtypes.

323 In conclusion, polygenic and transcriptional risk scores, both based on spirometry,
324 identified “high disease activity” and “severe disease risk” subtypes with distinct clinical and
325 biological characteristics. Proteomic and drug repurposing analysis identified subtype-specific
326 enrichment for therapies, some of which were previously hypothesized in COPD.

REFERENCES

1. Safiri, S. *et al.* Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. *BMJ* **378**, e069679 (2022).
2. Hurst, J. R. *et al.* Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *N. Engl. J. Med.* **363**, 1128–1138 (2010).
3. Wedzicha, J. A. The heterogeneity of chronic obstructive pulmonary disease. *Thorax* **55**, 631–632 (2000).
4. Natarajan, P. *et al.* Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. *Circulation* **135**, 2091–2101 (2017).
5. Rodon, J. *et al.* Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nat. Med.* **25**, 751–758 (2019).
6. Moll, M. *et al.* Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. *Lancet Respir. Med.* **8**, 696–708 (2020).
7. Moll, M. *et al.* Development of a Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* **205**, 161–170 (2022).
8. Zhang, J. *et al.* A Polygenic Risk Score and Age of Diagnosis of Chronic Obstructive Pulmonary Disease. *Eur. Respir. J.* 2101954 (2022) doi:10.1183/13993003.01954-2021.
9. Sun, J. *et al.* Translating polygenic risk scores for clinical use by estimating the confidence bounds of risk prediction. *Nat. Commun.* **12**, 5276 (2021).
10. Castaldi, P. J. *et al.* Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. *Thorax* **69**, 415–422 (2014).

11. Martinez, F. J. *et al.* Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. *Am. J. Respir. Crit. Care Med.* **205**, 275–287 (2022).
12. Serban, K. A. *et al.* Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease. *EBioMedicine* **84**, 104262 (2022).
13. Tibshirani, R., Walther, G. & Hastie, T. Estimating the Number of Clusters in a Data Set Via the Gap Statistic. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **63**, 411–423 (2001).
14. Khera, A. V. *et al.* Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. *Cell* **177**, 587-596.e9 (2019).
15. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
16. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **57**, 289–300 (1995).
17. Han, M. K. *et al.* Chronic Obstructive Pulmonary Disease Exacerbations in the COPD Gene Study: Associated Radiologic Phenotypes. *Radiology* **261**, 274–282 (2011).
18. Parr, D. G., Sevenoaks, M., Deng, C. Q., Stoel, B. C. & Stockley, R. A. Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; Methodological advances. *Respir. Res.* **9**, 1–8 (2008).
19. Van Tho, N. *et al.* A mixed phenotype of airway wall thickening and emphysema is associated with dyspnea and hospitalization for chronic obstructive pulmonary disease. *Ann. Am. Thorac. Soc.* **12**, 988–996 (2015).

20. Wang, R.-S. & Loscalzo, J. Network module-based drug repositioning for pulmonary arterial hypertension. *CPT Pharmacomet. Syst. Pharmacol.* **10**, 994–1005 (2021).
21. Fabregat, A. *et al.* Reactome pathway analysis: a high-performance in-memory approach. *BMC Bioinformatics* **18**, 142 (2017).
22. Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
23. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* **44**, W90-97 (2016).
24. Xie, Z. *et al.* Gene Set Knowledge Discovery with Enrichr. *Curr. Protoc.* **1**, e90 (2021).
25. Lowe, K. E. *et al.* COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. *Chronic Obstr. Pulm. Dis. Miami Fla* **6**, 384–399 (2019).
26. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
27. Radulescu, E. *et al.* Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain. *Mol. Psychiatry* **25**, 791–804 (2020).
28. Hu, X. *et al.* Polygenic transcriptome risk scores for COPD and lung function improve cross-ethnic portability of prediction in the NHLBI TOPMed program. *Am. J. Hum. Genet.* **109**, 857–870 (2022).
29. Mareckova, K. *et al.* Novel polygenic risk score as a translational tool linking depression-related changes in the corticolimbic transcriptome with neural face processing and anhedonic symptoms. *Transl. Psychiatry* **10**, 1–10 (2020).

30. Bandres-Ciga, S. *et al.* Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. *Acta Neuropathol. (Berl.)* **140**, 341–358 (2020).
31. Woodruff, P. G. *et al.* Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. *COPD* **8**, 21–29 (2011).
32. Wise, R. A. *et al.* Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. *Am. J. Respir. Crit. Care Med.* **206**, 838–845 (2022).
33. Zhang, R. *et al.* Novel disease associations with schizophrenia genetic risk revealed in ~400 000 UK Biobank participants. *Mol. Psychiatry* **27**, 1448–1454 (2022).
34. McDonald, M.-L. N. *et al.* It’s more than low BMI: prevalence of cachexia and associated mortality in COPD. *Respir. Res.* **20**, 100 (2019).
35. Grigsby, M. R. *et al.* Low Body Mass Index Is Associated with Higher Odds of COPD and Lower Lung Function in Low- and Middle-Income Countries. *COPD* **16**, 58–65 (2019).
36. Wada, H. *et al.* Low BMI and weight loss aggravate COPD mortality in men, findings from a large prospective cohort: the JACC study. *Sci. Rep.* **11**, 1531 (2021).
37. Mason, S. E. *et al.* Respiratory exacerbations are associated with muscle loss in current and former smokers. *Thorax* **76**, 554–560 (2021).
38. Eriksson, B. *et al.* Only severe COPD is associated with being underweight: results from a population survey. *ERJ Open Res.* **2**, 00051–02015 (2016).
39. Vanfleteren, L. E. G. W. *et al.* Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **187**, 728–735 (2013).

40. Collins, S. *et al.* Role of leptin in fat regulation. *Nature* **380**, 677 (1996).
41. La Cava, A. Leptin in inflammation and autoimmunity. *Cytokine* **98**, 51–58 (2017).
42. La Cava, A. & Matarese, G. The weight of leptin in immunity. *Nat. Rev. Immunol.* **4**, 371–379 (2004).
43. Matarese, G. *et al.* Balancing susceptibility to infection and autoimmunity: a role for leptin? *Trends Immunol.* **23**, 182–187 (2002).
44. Suzuki, M. *et al.* Lower Leptin/Adiponectin Ratio and Risk of Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease. *Ann. Am. Thorac. Soc.* **11**, 1511–1519 (2014).
45. Takabatake, N. *et al.* Circulating leptin in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **159**, 1215–1219 (1999).
46. Hansel, N. N. *et al.* Leptin receptor polymorphisms and lung function decline in COPD. *Eur. Respir. J.* **34**, 103–110 (2009).
47. Bruno, A. *et al.* Does leptin play a cytokine-like role within the airways of COPD patients? *Eur. Respir. J.* **26**, 398–405 (2005).
48. Vernooy, J. H. J. *et al.* Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. *Thorax* **64**, 26–32 (2009).
49. Sueblinvong, V. & Liangpunsakul, S. Relationship between serum leptin and chronic obstructive pulmonary disease in US adults: Results from NHANESIII. *J. Investig. Med. Off. Publ. Am. Fed. Clin. Res.* **62**, 934–937 (2014).
50. Curtis, J. L. Queens beat one-eyed jacks, but nobody’s played the ace yet. Adipokines as chronic obstructive pulmonary disease biomarkers. *Ann. Am. Thorac. Soc.* **12**, 971–973 (2015).

51. Oh, Y.-M. *et al.* Association of plasma adipokines with chronic obstructive pulmonary disease severity and progression. *Ann. Am. Thorac. Soc.* **12**, 1005–1012 (2015).
52. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat. Genet.* **51**, 584–591 (2019).

Table legends

Table 1: Characteristics of study populations. COPD = chronic obstructive pulmonary disease. COPDGene = Genetic Epidemiology of COPD. ECLIPSE = Evaluation of COPD to Longitudinally Identify Predictive Surrogate Endpoints study. FEV₁ = forced expiratory volume in 1 second. FEV₁/FVC = FEV1/forced vital capacity. NHW = non-Hispanic white. AA=African American.

Table 2: Omics-defined subtypes in the COPDGene testing set and ECLIPSE. The was defined as the "Low PRS, Low TRS" group. BMI = body-mass index. LAA = low attenuation area. HU = Hounsfield units. Perc15 = 15th percentile of lung density histogram on inspiratory CT scans. WA % = wall area percent. Pi10 = square root of wall area of a hypothetical internal perimeter of 10 mm. ACO = asthma-COPD overlap. See Table 1 legend for other abbreviations. NHW = non-Hispanic white. AA=African American.

Table 3. Multivariable linear regressions in the COPDGene testing sets and ECLIPSE. Models were adjusted or age, sex, current smoking status, pack-years of smoking, and principal components of genetic ancestry. Computed tomography imaging outcomes were additionally adjusted for CT scanner. Abbreviations are detailed in the Table 1 and 2 legends.

Figure legends

Figure 1: Schematic of study design. COPD = chronic obstructive pulmonary disease. COPDGene = Genetic Epidemiology of COPD study. ECLIPSE = Evaluation of COPD to Longitudinally Identify Predictive Surrogate Endpoints study. PRS = polygenic risk score. TRS = transcriptional risk score. STRING = Search Tool for the Retrieval of Interacting Genes/Proteins. MAGMA = Multi-marker Analysis of GenoMic Annotation.

Figure 2. Omics-defined groups or subtypes overlaid on a plot of the polygenic risk score (PRS; *x-axis*) and transcriptional risk score (TRS; *y-axis*) in the COPDGene testing set.

Figure 3. High disease activity (“low PRS, high TRS”) subtype STRING protein-protein interaction networks using differentially expressed proteins in Omics-defined groups (subtypes) in the COPDGene testing set as seed proteins, permitting up to 10 interactors in the first shell and 5 interactors in the second shell. Only high-confidence interactions were included and greater line thickness indicates greater confidence. Differentially expressed proteins were identified by comparing group assignments to the reference group. Colors represent MCL (Markov) clusters.

Figure 4: Severe disease risk (“high PRS, high TRS”) subtype STRING protein-protein interaction networks using differentially expressed proteins in Omics-defined groups (subtypes) in the COPDGene testing set as seed proteins, permitting up to 10 interactors in the first shell and 5 interactors in the second shell. Only high-confidence interactions were included and greater line thickness indicates greater confidence. Differentially expressed proteins were identified by comparing group assignments to the reference group. Colors represent MCL (Markov) clusters.

Table 1: Characteristics of study populations. COPD = chronic obstructive pulmonary disease. COPDGene = Genetic Epidemiology of COPD. ECLIPSE = Evaluation of COPD to Longitudinally Identify Predictive Surrogate Endpoints study. FEV₁ = forced expiratory volume in 1 second. FEV₁/FVC = FEV1/forced vital capacity. NHW = non-Hispanic white. AA=African American.


| <i>Characteristic</i> | <i>COPDGene training set</i> | <i>COPDGene testing set</i> | | <i>ECLIPSE</i> |
|-----------------------------------|------------------------------|-----------------------------|---------------|----------------|
| | <i>NHW</i> | <i>NHW</i> | <i>AA</i> | <i>NHW</i> |
| n | 1374 | 1133 | 299 | 468 |
| Age in years (mean (SD)) | 67.38 (8.25) | 68.13 (8.30) | 61.01 (6.95) | 64.43 (6.09) |
| Sex (No. % female) | 677 (49.3) | 560 (49.4) | 153 (51.2) | 156 (33.3) |
| Pack-years of smoking (mean (SD)) | 45.47 (24.61) | 45.47 (23.65) | 39.55 (20.74) | 49.33 (26.87) |
| Current smoking (No %) | 343 (25.0) | 289 (25.5) | 182 (60.9) | 70 (15.0) |
| FEV1 % predicted (mean (SD)) | 78.37 (24.21) | 77.85 (24.81) | 81.79 (23.54) | 44.22 (14.64) |
| FEV1/FVC (mean (SD)) | 0.67 (0.15) | 0.66 (0.15) | 0.71 (0.14) | 0.44 (0.11) |

Table 2: Omics-defined subtypes in the COPDGene testing set and ECLIPSE. The was defined as the "Low PRS, Low TRS" group. BMI = body-mass index. LAA = low attenuation area. HU = Hounsfield units. Perc15 = 15th percentile of lung density histogram on inspiratory CT scans. WA % = wall area percent. Pi10 = square root of wall area of a hypothetical internal perimeter of 10 mm. ACO = asthma-COPD overlap. See Table 1 legend for other abbreviations. NHW = non-Hispanic white. AA=African American.

| Characteristic | COPDGene NHW testing set | | | COPDGene AA testing set | | | ECLIPSE | | |
|--|---------------------------------------|----------------------|-----------------------|---------------------------------------|----------------------|-----------------------|------------------------------------|----------------------|-----------------------|
| | Reference group (Low PRS, Low TRS) | Low PRS, High TRS | High PRS, High TRS | Reference group (Low PRS, Low TRS) | Low PRS, High TRS | High PRS, High TRS | Reference group (Low PRS, Low TRS) | Low PRS, High TRS | High PRS, High TRS |
| n | 196 | 65 | 68 | 61 | 16 | 11 | 57 | 63 | 56 |
| Age in years (mean (SD)) | 67.85 (8.52) | 67.16 (6.46) | 69.04 (8.11) | 61.26 (7.55) | 60.58 (7.24) | 65.95 (8.05) | 63.00 (5.10) | 65.43 (6.65) | 66.59 (5.95) |
| Sex (No % female) | 114 (58.2) | 19 (29.2) | 24 (35.3) | 36 (59.0) | 5 (31.2) | 8 (72.7) | 30 (52.6) | 10 (15.9) | 11 (19.6) |
| Pack-years of smoking (mean (SD)) | 36.51 (22.27) | 60.07 (26.49) | 57.28 (23.35) | 37.01 (20.85) | 43.42 (16.14) | 61.36 (38.87) | 45.49 (26.24) | 55.29 (35.25) | 54.29 (21.10) |
| Current smoking (No. %) | 20 (10.2) | 36 (55.4) | 36 (52.9) | 31 (50.8) | 15 (93.8) | 8 (72.7) | 6 (10.5) | 7 (11.1) | 12 (21.4) |
| BMI (Kg/m ²) (mean (SD)) | 30.00 (6.84) | 26.51 (5.81) | 25.70 (5.58) | 30.61 (6.36) | 29.14 (8.52) | 25.26 (6.57) | 27.54 (5.06) | 26.70 (6.22) | 25.49 (4.76) |
| FEV1 % predicted (mean (SD)) | 90.15 (18.13) | 66.50 (27.07) | 60.55 (24.11) | 90.83 (17.41) | 80.61 (25.43) | 71.08 (10.67) | 50.25 (13.42) | 43.41 (15.65) | 37.44 (13.44) |
| FEV1/FVC (mean (SD)) | 0.75 (0.09) | 0.57 (0.15) | 0.53 (0.15) | 0.77 (0.10) | 0.73 (0.14) | 0.61 (0.12) | 45.84 (11.13) | 43.16 (12.79) | 39.71 (10.29) |
| % LAA < -950 HU (mean (SD)) | 2.78 (4.71) | 8.50 (10.39) | 11.00 (11.98) | 1.71 (4.00) | 3.51 (8.08) | 5.49 (7.30) | 16.01 (11.46) | 20.88 (13.50) | 22.44 (13.22) |
| Perc15 (mean (SD)) | -913.62 (20.43) | -927.23 (27.21) | -931.05 (31.55) | -895.53 (26.89) | -901.19 (29.94) | -913.62 (34.95) | -943.75 (50.13) | -960.00 (49.44) | -971.11 (45.84) |
| Pi10 (mean (SD)) | 2.01 (0.50) | 2.55 (0.65) | 2.60 (0.51) | 2.11 (0.48) | 2.56 (0.59) | 2.42 (0.44) | 4.38 (0.20) | 4.42 (0.23) | 4.43 (0.19) |
| WA % (mean (SD)) | 46.97 (8.11) | 54.46 (8.35) | 54.61 (7.41) | 47.48 (7.76) | 54.86 (10.52) | 51.62 (4.06) | 64.35 (2.79) | 65.05 (3.58) | 67.22 (3.44) |
| Change in FEV1 mL/year (prospective) (mean (SD)) | -32.11 (48.07) | -51.21 (74.41) | -66.45 (61.58) | -42.28 (36.59) | -87.86 (156.98) | -56.26 (76.62) | -32.21 (59.54) | -40.13 (75.31) | -15.22 (67.46) |

Table 3. Multivariable linear regressions in the COPDGene testing sets and ECLIPSE. Models were adjusted for age, sex, current smoking status, pack-years of smoking, and principal components of genetic ancestry. Computed tomography imaging outcomes were additionally adjusted for CT scanner. Abbreviations are detailed in the Table 1 and 2 legends.

| COPD-related outcome | COPDGene NHW testing set | | | | COPDGene AA testing set | | | | ECLIPSE | | | |
|-----------------------|--------------------------|----------|---------------------------|----------|------------------------------|-------|---------------------------|--------|------------------------------|-------|----------------------------|---------|
| | <i>Low PRS, High TRS</i> | | <i>High PRS, High TRS</i> | | <i>Low PRS, High TRS</i> | | <i>High PRS, High TRS</i> | | <i>Low PRS, High TRS</i> | | <i>High PRS, High TRS</i> | |
| | beta (95% CI) | p | beta (95% CI) | p | beta (95% CI) | p | beta (95% CI) | p | beta (95% CI) | p | beta (95% CI) | p |
| FEV1 % predicted | -22.3 (-29.5 to -15.2) | 4.3E-09 | -31.5 (-38.2 to -24.8) | 1E-17 | -4.11 (-16.8 to 8.59) | 0.53 | -19.6 (-32.7 to -6.51) | 0.0048 | -7.8 (-13.6 to -1.95) | 0.01 | -15.5 (-21.4 to -9.61) | 1.3E-06 |
| FEV1/FVC | -0.147 (-0.184 to -0.11) | 3E-13 | -0.197 (-0.233 to -0.161) | 4.8E-22 | -0.00368 (-0.0731 to 0.0657) | 0.92 | -0.118 (-0.193 to -0.043) | 0.0032 | -4.5 (-9.07 to 0.0772) | 0.057 | -8.83 (-13.5 to -4.16) | 0.0001 |
| % LAA < -950 HU | 3.1 (1.8 to 5.2) | 3.30E-05 | 3.4 (2.1 to 5.6) | 2.30E-06 | 1.3 (0.44 to 3.7) | 0.66 | 0.94 (0.23 to 3.9) | 0.93 | 2.33 (-3.34 to 8) | 0.42 | 6.97 (-0.0748 to 14) | 0.05 |
| Perc15 | -11.2 (-18.6 to -3.72) | 0.0037 | -15.3 (-22.8 to -7.89) | 7.6E-05 | -0.305 (-17.1 to 16.5) | 0.97 | -4.66 (-26.2 to 16.9) | 0.67 | -0.994 (-24.1 to 22.1) | 0.93 | -19.2 (-49.3 to 10.8) | 0.21 |
| Pi10 | 0.498 (0.298 to 0.698) | 2.10E-06 | 0.605 (0.429 to 0.78) | 1.40E-10 | 0.346 (-0.032 to 0.724) | 0.079 | 0.475 (0.00489 to 0.946) | 0.054 | -0.0786 (-0.147 to -0.00988) | 0.029 | -0.0753 (-0.163 to 0.0124) | 0.09 |
| WA % | 5.88 (3.19 to 8.58) | 2.90E-05 | 7.17 (4.63 to 9.71) | 8.90E-08 | 4.55 (-1.6 to 10.7) | 0.15 | 7.48 (0.0534 to 15) | 0.058 | 0.516 (-0.972 to 2) | 0.5 | 2.18 (0.376 to 3.98) | 0.02 |
| FEV1 change (mL/year) | -30 (-70.6 to 10.7) | 0.15 | -43.9 (-91.7 to 3.94) | 0.077 | -103 (-294 to 87.5) | 0.32 | -60.5 (-105 to -15.6) | 0.033 | -23.7 (-52.9 to 5.47) | 0.11 | 6.97 (-25.8 to 39.8) | 0.68 |



COPDGenetic training set
(NHW: n=1,374)

Determine
PRS and TRS
splits

COPDGenetic testing set
(NHW: n=1,133
AA: n=299)

ECLIPSE
(n=468)

Apply risk
score cut offs
and define
subtypes

Identify differentially
expressed proteins associated
with subtypes

- STRING analysis
- Enrichr/MAGMA drug repurposing analysis

Regression analyses of
subtype associations with
clinical outcomes

